<SEC-DOCUMENT>0001104659-23-066056.txt : 20230530
<SEC-HEADER>0001104659-23-066056.hdr.sgml : 20230530
<ACCEPTANCE-DATETIME>20230530162014
ACCESSION NUMBER:		0001104659-23-066056
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230530
FILED AS OF DATE:		20230530
DATE AS OF CHANGE:		20230530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		23976714

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2317272d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM 6-K</B></FONT><B><BR>
<BR>
</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of May 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&#120;</FONT></P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="text-align: center; width: 14%">
<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 30, 2023, CureVac N.V. (the &ldquo;Company&rdquo;) issued a
press release announcing the Company&rsquo;s financial results and business updates for the first quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Form 6-K (including
Exhibit 99.1, but excluding the statements of the Company&rsquo;s Chief Executive Officer and Chief Financial Officer contained in Exhibit&nbsp;99.1
hereto) is hereby incorporated by reference into the Company&rsquo;s Registration Statement on Form F-3 (File No. 333-259613).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 53%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 23%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Alexander Zehnder</FONT></TD>
    <TD STYLE="vertical-align: top; width: 23%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 86px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><A HREF="tm2317272d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2317272d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac N.V. Press Release dated May 30, 2023</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2317272d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B><IMG SRC="tm2317272d1_ex99-1img001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 32pt 0pt 175pt; text-indent: -143.2pt"><B>CureVac Announces Financial
Results for the First Quarter of 2023 and Provides Business Update&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="padding-right: 25pt">Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued
execution on infectious disease development program in collaboration with GSK</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; padding-right: 20pt">Filed infringement counterclaim in U.S. patent litigation with Pfizer/BioNTech; case
filed under nine CureVac patents; litigation timeline expected to be accelerated by successful court transfer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.1pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; padding-right: 24pt">Received positive preliminary opinion of German Federal Patent Court supporting validity
of German patent challenged in nullity action by Pfizer/BioNTech; German litigation broadened by additional CureVac patent</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.1pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify">Cash and cash equivalents position of &euro;617.5 million as of March 31, 2023</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>T&Uuml;BINGEN,
Germany/BOSTON, USA &ndash; May 30, 2023 </B></FONT>&ndash; CureVac N.V. (Nasdaq: CVAC) (&ldquo;CureVac&rdquo;), a global biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), today announced
financial results for the first quarter of 2023 and provided a business update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;During the first quarter of 2023, we continued
to execute on our multipronged clinical development strategy in prophylactic vaccines with the initiation of a Phase 1/2 clinical study
in seasonal flu, evaluating multivalent, modified mRNA vaccine candidates. In oncology, the first proof-of-principle clinical study to
validate our second-generation mRNA backbone in patients with glioblastoma has been activated and is expected to start recruitment shortly,&rdquo;
said Alexander Zehnder, Chief Executive Officer at CureVac. &ldquo;As we continue to make progress with our pipeline, we are also seeing
progress in our efforts to have our intellectual property innovations recognized. Our scientists have pioneered fundamental breakthroughs
in mRNA technology over the last two decades. These contributions have underpinned many developments in the mRNA field and resulted in
a broad IP portfolio that we intent to defend and further strengthen in pursuit of our mission to leverage our mRNA technology for the
development of transformative medicines.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&ldquo;In the first quarter of 2023, we
successfully raised $250 million in gross proceeds in a follow-on offering, extending our cash runway into 2025 and successfully diversifying
our investor base with new healthcare-specialized shareholders that share the company&rsquo;s vision&rdquo; said Pierre Kemula, Chief
Financial Officer of CureVac. &ldquo;We continue to build the company and advance our pipeline based on our unique mRNA technology to
bring new and better solutions to people and patients in need.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2317272d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selected Business Updates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prophylactic Vaccines</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Executing on Broad Second-Generation mRNA Vaccine Program, Jointly
Developed with GSK</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac continues to advance its broad clinical
development program in prophylactic vaccines in collaboration with GSK. Positive preliminary data reported in early 2023 from Phase 1
studies with modified, monovalent mRNA candidates in COVID-19 and flu provided strong validation of CureVac&rsquo;s mRNA technology platform.
All jointly tested candidates are based on CureVac&rsquo;s proprietary second-generation mRNA backbone, targeting improved intracellular
mRNA translation for early and strong immune responses. The second-generation mRNA backbone is expected to enable protection against
one or more emerging COVID-19 variants or multiple strains of other infectious diseases, such as flu, with potential for combination
vaccines against multiple different viruses as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The flu clinical development program was broadened
on May 8, 2023, when dosing of the first participant was announced in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified
mRNA seasonal flu vaccine candidates. The study evaluates flu vaccine candidates for safety, reactogenicity and immune responses. The
first, Phase 1 part of the trial is being conducted in the U.S. and Belgium. The tested multivalent vaccine candidates address all four
WHO-recommended flu strains and are compared to a licensed flu comparator vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Protection of Intellectual Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Over the last 23 years, CureVac has developed
proprietary foundational technology related to mRNA design, delivery and manufacturing that has materially contributed to the development
of safe and efficacious COVID-19 vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, CureVac announced the granting of its
motion to transfer U.S. patent litigation initiated by Pfizer/BioNTech in late July 2022 from the federal district court of Massachusetts
to the Eastern District of Virginia. The transfer is expected to significantly accelerate progress of the litigation, allowing for a likely
2024 trial date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">The motion to transfer the case is part
of a broadened counterclaim CureVac filed on May 19, 2023, that alleges infringement of nine U.S. patents by the manufacture and sale
of the SARS-CoV-2 vaccine Comirnaty&reg;: 11,135,312; 11,149,278; 11,286,492; 11,345,920; 10,760,070; 11,241,493; 11,471,525; 11,576,966;
and 11,596,686. This significantly expands the scope of the case beyond the three patents for which Pfizer/BioNTech had originally sought
confirmation of non-infringement. These nine patents cover foundational and highly relevant separate innovations in mRNA vaccine design,
formulation and manufacturing specific to SARS-CoV-2 vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Corresponding patent litigation in Germany
has been ongoing since June 2022. One of the patents at issue (EP 1 857 122) was challenged in a nullity action by Pfizer/BioNTech
in September 2022. A preliminary opinion issued in April 2023 by the German Federal Patent Court supports the validity of the
patent. The German litigation, which originated with a filing by CureVac regarding four of its intellectual property rights, now
also covers a fifth intellectual property right (EP 3 708 668 B1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2317272d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac does not seek an injunction nor intend
to take legal action that impedes the production, sale or distribution of Comirnaty&reg; by BioNTech and its partner Pfizer. The development
of safe and efficacious COVID-19 vaccines is based on decades of scientific research and innovation, supported by CureVac as the earliest
pioneer in mRNA technology. Accordingly, CureVac&rsquo;s intellectual property rights need to be acknowledged and respected in the form
of fair compensation that enables reinvestment into the further advancement of mRNA technology and the ongoing development of new classes
of life-saving medicines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Update for the First Quarter of 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Position</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Cash and cash equivalents amounted to
 &euro;617.5 million at the end of March 2023, increasing from &euro;495.8 million at the end of 2022. The increase was mainly driven by
 &euro;219.8 million in net proceeds raised in a follow-on offering during February 2023. In the first three months of 2023, cash used
in operations was mainly allocated to payments in connection with ongoing R&amp;D activities and the purchase of raw materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Revenues amounted to &euro;7.1 million
for the first quarter of 2023, representing a decrease of &euro;17.3 million, or 71%, from &euro;24.4 million for the same period in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The decrease was primarily driven by lower revenues from the two GSK
collaborations. For both GSK collaboration agreements, total revenues of &euro;6.5 million were recognized for the three months ending
March 31, 2023, compared to &euro;23.7 million in the prior year period at which point an important part of the milestone related to
starting the flu clinical trial in Panama was recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Operating Result</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating loss amounted to &euro;60.4 million
for the first quarter of 2023, representing an increase of &euro;45.1 million, from &euro;15.3 million for the same period in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The operating result was affected by several key drivers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.1pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify; padding-right: 1pt">Cost of sales decreased primarily in relation to lower write-off of raw materials.
In addition, the first quarter of 2022 was impacted by additional costs related to the termination of CMO activities for the first generation
COVID-19 vaccine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.1pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Research and development expenses increased primarily with enhanced activity in infectious disease and
oncology R&amp;D projects and development of the workforce. The first quarter of 2022 was positively impacted by &euro;6.8 million related
to the reversal of an outstanding CRO provision. Additionally, in the first quarter of 2022, Research and Development costs were positively
impacted by a one-off net gain for a change in the contract termination
provision resulting primarily in GSK taking over, from the Company, committed capacity at a CMO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 420pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2317272d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.1pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify">In the first quarter of 2022, other income was positively impacted by a one-off compensation from GSK
amounting to &euro;32.5 million for reimbursement of prepayments and production set-up activities at a CMO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financial Result (Finance Income and Expenses)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Net financial result for the first quarter
of 2023, amounted to &euro;3.0 million, or an increase of &euro;2.9 million from &euro;0.1 million for the same period in 2022. This was
mainly driven by interest income on cash investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Pre-Tax Loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Pre-tax loss was &euro;57.4 million for
the first quarter of 2023 compared to &euro;15.2 million in the same period of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Media and Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 62pt 0pt 0">Dr. Sarah Fakih, Vice President Corporate Communications
and Investor Relations CureVac, T&uuml;bingen, Germany&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +49 7071 9883-1298&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 310pt 0pt 0">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 310pt 0pt 0"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2317272d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">This press release contains statements
that constitute &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform
Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of
CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate
Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future
events or future results, in contrast with statements that reflect historical facts. Examples include statements regarding the completion,
size and terms of the proposed public offering. In some cases, you can identify such forward-looking statements by terminology such as
 &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo;
 &ldquo;project,&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking statements are based
on management&rsquo;s current beliefs and assumptions and on information currently available to the company. However, these forward-looking
statements are not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such statements. Forward-looking
statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions
and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and
future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties
and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed
legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company&rsquo;s industry,
the effects of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability to manage growth, reliance on
key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results
due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties
may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks
are outside of the company&rsquo;s control and could cause its actual results to differ materially from those it thought would occur.
The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and
specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&rsquo;s reports
and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC
website at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2317272d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cash and Condensed Consolidated Profit and Loss
Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">(in &euro; millions)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 14%; font-size: 10pt; font-weight: bold; text-align: right">495.8</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 14%; font-size: 10pt; font-weight: bold; text-align: right">617.5</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three months ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">(in &euro; millions)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font-size: 10pt">Revenue</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">24.4</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">7.1</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Cost of Sales, Operating Expenses &amp; Other Operating Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-39.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-67.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating Result</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">-15.3</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">-60.4</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Financial Result</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3.0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Pre-Tax Loss</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">-15.2</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">-57.4</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2317272d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2317272d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ *T# 2(  A$! Q$!_\0
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M URVUAO&7]H7:VGB+2IIDL[.SMGZ7-DA5B#"1@HS%I5=B6W*N/7** /G_P"
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-W'"@X&3ZUU=% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
